Header Logo

Connection

ERIC JONASCH to Prognosis

Back to Details
This is a "connection" page, showing publications ERIC JONASCH has written about Prognosis.
ERIC JONASCH
Connection Strength
0.676
Prognosis
  1. Prognostic models: from the fates to the future. Cancer. 2009 May 15; 115(10):2028-30.
    View in: PubMed
    Score: 0.098
  2. Management of Brain Metastases in Metastatic Renal Cell Carcinoma. Hematol Oncol Clin North Am. 2023 10; 37(5):1005-1014.
    View in: PubMed
    Score: 0.065
  3. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021 04; 17(4):245-261.
    View in: PubMed
    Score: 0.054
  4. Updates to the Management of Kidney Cancer. J Natl Compr Canc Netw. 2018 05; 16(5S):639-641.
    View in: PubMed
    Score: 0.046
  5. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1300-4.
    View in: PubMed
    Score: 0.036
  6. Renal cell carcinoma. BMJ. 2014 Nov 10; 349:g4797.
    View in: PubMed
    Score: 0.036
  7. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011 Nov; 24(11):1470-9.
    View in: PubMed
    Score: 0.028
  8. Prognostic and predictive factors in the targeted therapy era: filling in the blanks. Curr Oncol Rep. 2010 May; 12(3):143-5.
    View in: PubMed
    Score: 0.026
  9. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872.
    View in: PubMed
    Score: 0.023
  10. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021 12; 22(12):1732-1739.
    View in: PubMed
    Score: 0.015
  11. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904.
    View in: PubMed
    Score: 0.014
  12. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.
    View in: PubMed
    Score: 0.014
  13. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.014
  14. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021 05 27; 184(11):2988-3005.e16.
    View in: PubMed
    Score: 0.014
  15. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073.
    View in: PubMed
    Score: 0.014
  16. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
    View in: PubMed
    Score: 0.013
  17. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 06; 17(3):e526-e533.
    View in: PubMed
    Score: 0.012
  18. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist. 2019 04; 24(4):491-497.
    View in: PubMed
    Score: 0.012
  19. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics. 2017 Oct 03; 18(Suppl 6):678.
    View in: PubMed
    Score: 0.011
  20. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.011
  21. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget. 2017 Jun 27; 8(26):42149-42158.
    View in: PubMed
    Score: 0.011
  22. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 06; 15(6):804-834.
    View in: PubMed
    Score: 0.011
  23. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.010
  24. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol. 2016 Aug; 26(8):2798-807.
    View in: PubMed
    Score: 0.010
  25. The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. Radiology. 2015 Oct; 277(1):114-23.
    View in: PubMed
    Score: 0.009
  26. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.009
  27. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother. 2015 Apr; 16(6):805-19.
    View in: PubMed
    Score: 0.009
  28. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
    View in: PubMed
    Score: 0.008
  29. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol. 2013 Aug; 190(2):407-16.
    View in: PubMed
    Score: 0.008
  30. Clinical genomics of renal epithelial tumors. Cancer Genet. 2011 Jun; 204(6):285-97.
    View in: PubMed
    Score: 0.007
  31. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.007
  32. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900.
    View in: PubMed
    Score: 0.005
  33. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May; 69(5):835-8.
    View in: PubMed
    Score: 0.005
  34. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7.
    View in: PubMed
    Score: 0.005
  35. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.